Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Return on Equity (2016 - 2025)

Moleculin Biotech's Return on Equity history spans 10 years, with the latest figure at 4.2% for Q4 2025.

  • Quarterly results put Return on Equity at 4.2% for Q4 2025, up 602.0% from a year ago — trailing twelve months through Dec 2025 was 4.2% (up 602.0% YoY), and the annual figure for FY2025 was 1.91%, down 67.0%.
  • Return on Equity for Q4 2025 was 4.2% at Moleculin Biotech, up from 1.58% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 4.2% in Q4 2025 to a low of 4.95% in Q2 2025.
  • The 5-year median for Return on Equity is 1.09% (2022), against an average of 1.05%.
  • Peak annual rise in Return on Equity hit 602bps in 2025, while the deepest fall reached -229bps in 2025.
  • Year by year, Return on Equity stood at 0.52% in 2021, then plummeted by -94bps to 1.01% in 2022, then tumbled by -81bps to 1.83% in 2023, then rose by 1bps to 1.82% in 2024, then soared by 330bps to 4.2% in 2025.
  • According to Business Quant data, Return on Equity over the past three periods came in at 4.2%, 1.58%, and 4.95% for Q4 2025, Q3 2025, and Q2 2025 respectively.